Keren Haruvi, the Association for Accessible Medicines’ newly appointed chair, speaks well and passionately about the many challenges facing the US generics market. Elevated from vice chair at the turn of last year, Haruvi brings to bear her two decades of industry experience, including her current role as president of Sandoz North America.
‘Is The Market Now Sustainable? The Answer Is Still Not’: AAM’s Haruvi On The Need To Fix The US Generics Industry
Newly Appointed Chair And Sandoz Exec Sits For Exclusive Interview With Generics Bulletin
Dramatic downward pressure on prices will continue to impact supply for an industry already reeling from shortages, the Association for Accessible Medicines’ newly appointed chair Keren Haruvi tells Generics Bulletin during an exclusive interview on the sidelines of the association’s recent annual conference in Tampa.
More from Biosimilars
More from Conferences
• By
IGBA secretary general Susana Almeida takes Generics Bulletin through an almost two-decade journey of developing global regulatory convergence and the next goals for the off-patent industry.
• By
As the US marks 10 years since the first biosimilar approval and launch, AAM Biosimilars Council executive director Craig Burton talks to Generics Bulletin about the lessons learned so far and the path ahead, including how to move on from market models that have proved to be “not appropriate” for biosimilars.
• By
Tariffs, international cooperation, and war: the off-patent industry is not immune to the political issues raging across the globe. Medicines for Europe’s Adrian van den Hoven and Beata Stepniewska spoke with Generics Bulletin about what these developments mean for the sector.